A nationwide Swedish target trial reported a 49% lower 10‐year risk of MALO among GLP‐1 RA initiators with chronic liver disease and T2D, though estimates were imprecise (95% CI 0.50–1.32; n = 1026 vs. 15 633) [16]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.